The board of directors of Antengene Corporation Limited announced that Mr. Mark J. Alles ("Mr. Alles") has tendered his resignation as an independent non-executive director, the chairman of the nomination and corporate governance committee of the Company, a member of each of the audit committee and the remuneration committee of the Company with effect from April 14, 2023 in order to pursue other new opportunities taking an executive role within the pharmaceutical industry, which may or may not give rise to a potential conflict of interests. Mr. Yilun Liu ("Mr. Liu") has tendered his resignation as a non-executive director of the Company with effect from April 14, 2023 due to his own business engagement which requires more of his attention and dedication. In addition, the Board announced that Dr. Rafael Fonseca ("Dr. Fonseca") has been appointed as an independent non-executive director of the Company with effect from April 14, 2023.

Dr. Fonseca, aged 56, is the Getz Family Professor of Cancer, Professor of Medicine, Chief Innovation Officer at the Mayo Clinic in Arizona and a member of the Mayo Clinic Board of Governors and Board of Trustees. Throughout his training and career, Dr Fonseca has received numerous awards and honors, including the Damon Runyon-Walter Winchell Clinical Investigator Award and the International Waldenström Macroglobulinemia Research Award. He is a Mayo Clinic Distinguished Investigator, the highest academic distinction given to investigators at his institution.

He holds memberships and serves in positions for organizations such as the American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), American Association for Cancer Research, and the International Myeloma Society. His research has been funded by the National Cancer Institute (R01, P01, SPORE), the Leukemia & Lymphoma Society, the Multiple Myeloma Research Fund, and the Damon Runyon Cancer Research Fund. Dr Fonseca serves as a reviewer and in editorial capacities for medical publications including Blood, Lancet, The changes in the board committees following the resignation of Mr. Alles are as follows: (1) Dr. Jay Mei (" Dr. Mei ") has been appointed as the chairman of the Nomination and Corporate Governance Committee; Dr. Fonseca has been appointed as a member of the Audit Committee and the Nomination and Corporate Governance Committee; and Mr. Sheng Tang (" Mr. Tang ") has been appointed as a member of the Remuneration Committee.

The Board announced that it has established the scientific committee for the purposes of, among others, providing independent scientific advice to the board of directors and management team with effect from April 14, 2023. The Scientific Committee also reviews and evaluates research and development strategy and plans, monitors progress, provides advice on scientific and technical aspects, oversees compliance with ethical and regulatory requirements, and communicates with the scientific community and the public. Dr. Fonseca has been appointed as the chairman of the Scientific Committee, while Dr. Mei and Dr. Kan Chen ("Dr. Chen") have been appointed as members of the Scientific Committee.